Jula Inrig Sells 7,215 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Key Points

• Jula Inrig sold 7,215 shares of Travere (NASDAQ:TVTX) on April 14 at an average price of $41.93 for roughly $302,525 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vested equity, cutting her stake by 6.03% to 112,491 shares.
• Filspari approval drove momentum: The FDA granted full approval for Filspari in FSGS, prompting about a 37% rally and multiple analyst price-target upgrades (consensus "Moderate Buy", average target $42.50), though trading has been volatile with elevated volume.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 7,215 shares of the business's stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $41.93, for a total value of $302,524.95. Following the transaction, the insider owned 112,491 shares of the company's stock, valued at $4,716,747.63. This trade represents a 6.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The stock was sold at an average price of $42.61, for a total value of $43,376.98.
• On Wednesday, February 4th, Jula Inrig sold 1,779 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.21, for a total value of $57,301.59.
• On Tuesday, February 3rd, Jula Inrig sold 6,956 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.12, for a total value of $223,426.72.

Travere Therapeutics Trading Down 2.8%

TVTX traded down $1.18 during trading hours on Wednesday, reaching $40.95. 4,521,912 shares of the company's stock traded hands, compared to its average volume of 2,203,580. The firm has a 50-day moving average price of $29.57 and a 200 day moving average price of $31.37. The firm has a market capitalization of $3.78 billion, a PE ratio of -136.50 and a beta of 0.86. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $43.31.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Emerald Advisers LLC raised its holdings in shares of Travere Therapeutics by 2.6% in the third quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company's stock valued at $51,308,000 after acquiring an additional 55,407 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in Travere Therapeutics during the 3rd quarter worth about $3,872,000. Palisades Investment Partners LLC bought a new position in Travere Therapeutics during the 4th quarter worth about $5,264,000. Voya Investment Management LLC increased its position in Travere Therapeutics by 16.2% during the 3rd quarter. Voya Investment Management LLC now owns 194,854 shares of the company's stock valued at $4,657,000 after purchasing an additional 27,133 shares during the period. Finally, Lisanti Capital Growth LLC purchased a new position in Travere Therapeutics during the 3rd quarter valued at about $3,095,000.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TVTX shares. Guggenheim upped their price target on shares of Travere Therapeutics from $49.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday. Wall Street Zen lowered shares of Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 21st. HC Wainwright reissued a "buy" rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research report on Tuesday. Wedbush upped their target price on shares of Travere Therapeutics from $39.00 to $44.00 and gave the stock an "outperform" rating in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $42.50.

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.